Hyloris Pharmaceuticals (LTS:0AB6) Ending Cash Position: €13.78 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
11 GF Score
Price €4.50
GF Value €9.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Ending Cash Position?

Hyloris Pharmaceuticals LTS:0AB6 11 Ending Cash Position is €13.78 Mil as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 11/100 and a GF Value™ of €9.77 (Possible Value Trap). The stock has 3 warning signs investors should review.

Hyloris Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 was €13.78 Mil.

Hyloris Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2024 (€23.59 Mil) to Jun. 2025 (€18.62 Mil) and declined from Jun. 2025 (€18.62 Mil) to Dec. 2025 (€13.78 Mil).

Hyloris Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 (€30.41 Mil) to Dec. 2024 (€23.59 Mil) and declined from Dec. 2024 (€23.59 Mil) to Dec. 2025 (€13.78 Mil).

Hyloris Pharmaceuticals Ending Cash Position Related Terms

Hyloris Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals Ending Cash Position Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.01 33.46 30.41 23.59 13.78

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.41 27.43 23.59 18.62 13.78
LTS:0AB6
11GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hyloris Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=23.595+-9.82
=13.78

Hyloris Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=18.616+-4.841
=13.78

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €13.78 Mil mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Ending Cash Position of €13.78 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Ending Cash Position too high?
Hyloris Pharmaceuticals' current Ending Cash Position is €13.78 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 11/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Ending Cash Position compare to VRTX and REGN?
Hyloris Pharmaceuticals' Ending Cash Position of €13.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Ending Cash Position is €13.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.77, compared to a current price of €4.50 — trading 53.9% below its estimated fair value. The current Ending Cash Position is €13.78 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Ending Cash Position is €13.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.50 is trading 53.9% below its estimated GF Value™ of €9.77. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0AB6:

  • Ending Cash Position: €13.78 Mil
  • GF Value™: €9.77 vs. price of €4.50 (53.9% below fair value)
  • GF Score™: 11/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
11GF Score

Get the complete analysis for LTS:0AB6

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.50
Price
€9.77
GF Value